Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

ONJ in two dental practice-based research network regions.

Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, Richman J; DPBRN Collaborative Group.

Tex Dent J. 2013 Apr;130(4):311-8.

PMID:
23767160
2.

ONJ in two dental practice-based research network regions.

Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, Richman J; DPBRN Collaborative Group.

J Dent Res. 2011 Apr;90(4):433-8. doi: 10.1177/0022034510387795. Epub 2011 Feb 11.

3.
4.

Risks for jaw osteonecrosis drastically increases after 2 years of bisphosphonate therapy.

Akintoye SO, Hersh EV.

J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):251-3. doi: 10.1016/S1532-3382(12)70048-9.

PMID:
23253854
5.

Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.

Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S.

Osteoporos Int. 2007 Oct;18(10):1363-70. Epub 2007 Jun 28.

PMID:
17598065
6.

Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.

Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):810-7. doi: 10.1002/pds.3292. Epub 2012 Jun 19.

PMID:
22711458
7.

Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.

Khan AA, Rios LP, Sándor GK, Khan N, Peters E, Rahman MO, Clokie CM, Dore E, Dubois S.

J Rheumatol. 2011 Jul;38(7):1396-402. doi: 10.3899/jrheum.100221. Epub 2011 Apr 15.

PMID:
21498483
8.

Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN.

Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE; CONDOR Collaborative Group, Beadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W.

J Dent Res. 2011 Apr;90(4):439-44. doi: 10.1177/0022034510397196. Epub 2011 Feb 11.

9.

Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.

Gebara SN, Moubayed H.

Am J Health Syst Pharm. 2009 Sep 1;66(17):1541-7. doi: 10.2146/ajhp080251. Review.

PMID:
19710437
10.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Mavrokokki T, Cheng A, Stein B, Goss A.

J Oral Maxillofac Surg. 2007 Mar;65(3):415-23.

PMID:
17307586
11.

Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E; American Society for Bone and Mineral Research.

J Bone Miner Res. 2007 Oct;22(10):1479-91.

12.

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.

Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA.

J Clin Oncol. 2005 Dec 1;23(34):8580-7.

PMID:
16314620
13.

Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.

Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M.

Gynecol Oncol. 2009 Mar;112(3):605-9. doi: 10.1016/j.ygyno.2008.11.029. Epub 2009 Jan 12.

PMID:
19136147
14.

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.

King AE, Umland EM.

Pharmacotherapy. 2008 May;28(5):667-77. doi: 10.1592/phco.28.5.667. Review.

PMID:
18447663
15.

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.

Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2.

PMID:
20361252
16.

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.

Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26.

PMID:
18602738
17.

Bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Taskforce on Osteonecrosis of the Jaw.

J Rheumatol. 2009 Mar;36(3):478-90. doi: 10.3899/jrheum.080759. Review.

PMID:
19286860
18.

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.

Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY.

Bone. 2008 May;42(5):841-7. doi: 10.1016/j.bone.2008.01.003. Epub 2008 Jan 18. Review.

PMID:
18314405
19.

Practical considerations for treatment of patients taking bisphosphonate medications: an update.

Brock G, Barker K, Butterworth CJ, Rogers S.

Dent Update. 2011 Jun;38(5):313-4, 317-8, 321-4 passim. Review.

PMID:
21834312
20.

Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy.

Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS.

J Oral Maxillofac Surg. 2013 Mar;71(3):513-9. doi: 10.1016/j.joms.2012.07.049. Epub 2012 Sep 19.

PMID:
22999296

Supplemental Content

Support Center